CompletedNot Applicable

18F-Fluorocholine (18F-FCho) to Distinguish Necrosis From Recurrence in Brain Metastases

United States19 participantsStarted 2014-01

Plain-language summary

The main purpose of this study is to determine the distribution of 18F Fluorocholine (18F-FCH) in the brain which can help distinguishing radiation-induced scarring from tumor regrowth. In addition, the study will measure levels of 18F-FCH in the blood and (if applicable) in the brain lesion tissue that is removed as part of the planned brain surgery.

Who can participate

Age range21 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Patient and/or guardian is able to provide written informed consent prior to study registration * Age ≥ 21 years old * Evolving brain lesions post SRS requiring neurosurgical resection (whether for symptomatic control or to establish pathology) Exclusion Criteria: * Inability to undergo a MRI or PET scan (e.g., claustrophobia or metal implant) * Pregnant or nursing female * Unable to cooperate for PET/CT

What they're measuring

to distinguish radiation necrosis from progressive tumor

Timeframe: 1 year

Trial details

NCT IDNCT02037945

SponsorMemorial Sloan Kettering Cancer Center

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2022-12-08

View on ClinicalTrials.gov More Brain Metastases trials